The U.S. Food and Drug Administration late Friday allowed the drug remdesivir to be used on all patients hospitalized with COVID-19, although no published research supports such widespread use.
The move, which comes less than a week after the agency approved use of convalescent plasma – also with no published scientific support – has fueled concerns the agency is yielding to political pressure.
“It seems to be a pattern of approval without science, without data, without evidence,” said Dr. Eric Topol, vice president for research at Scripps Research in La Jolla, California and a national expert on the use of data in medical research.
In May, the FDA allowed remdesivir to be used for hospitalized patients who need oxygen, but not those sick enough to require ventilation. A government study published that month in the New England Journal of Medicine found those patients recovered faster than those who hadn’t gotten the drug, though there was no evidence that it saved lives.
No studies have been publishedsince then supporting more widespread use of remdesivir, yet the FDA said the data is now compelling enough to expand its use.
“The data show that this treatment has the potential to help even more hospitalized patients who are suffering from the effects of this devastating virus,” FDA Commissioner Dr. Stephen M. Hahn said in a prepared statement announcing the agency had granted an emergency use authorization for remdesivir.
The FDA uses that process to approve products that, based on scientific evidence, it is “reasonable to believe … may be effective.” An emergency use authorization can be issued only during an emergency, such as the COVID-19 pandemic, when there are no adequate, approved and available alternatives.
Topol said he was appalled by the expanded approval of the drug. “There are no data to support wide use of remdesivir,” he said. “This is extraordinary.”
Operation Warp Speed:Coronavirus vaccine on track for FDA approval by end of 2020, official says
The FDA announced the expanded use of remdesivir at 5:20 p.m. ET on Friday, citing two studies to support its decision. One was the study published in May.
The other, released earlier this month, found that five days of treatment with the drug was just as effective as 10, allowing supplies of the sought-after drug to be stretched. That study was conducted by the drugmaker, Gilead Sciences Inc. of Foster City, California.
In a statement, Gilead’s chief medical officer Dr. Merdad Parsey said the company was pleased with the FDA’s decision to expand use of the drug, which he referred to by its trade name.
“As we learn more about COVID-19 and we further establish the efficacy and safety profile of Veklury, we see benefit to making the drug available to patients at earlier stages of the disease,” he wrote.
Will expanded use of remdesivir help patients?
Dr. Nuala Meyer, a critical care physician and scientist at the Perelman School of Medicine and the Hospital of the University of Pennsylvania, said she was surprised by the FDA’s decision.
“We always expect the FDA to base decisions on data and we do get concerned when we see decision-making that we can’t find the data to support,” she said.
But she doesn’t think it will change much at her hospital. Patients at PennMed are given remdesivir only if they have pneumonia requiring supplemental oxygen. That would have accounted for more than half of the patients during Philadelphia’s surge in April and May, Meyer said, but fewer today.
Most of her current patients, she said, are in the hospital for about 48 hours, so it wouldn’t make sense to put them on remdesivir, an intraveneous therapy with a five-day course. “I’m not aware of a whole lot of data in hospitalized patients who don’t require oxygen,” she said.
Meyer is concerned that the expanded use may make it harder to get the drug for patients who need it. “We would certainly prioritize patients in whom it is shown to have a benefit.”
FDA under fire for coronavirus response
Hahn, a radiation oncologist and former chief medical executive of the MD Anderson Cancer Center in Houston, has been FDA commissioner only since December, but this is the fourth time he has run afoul of the scientific community for his agency’s actions to combat the coronavirus.
In March, the FDA allowed makers of COVID-19 antibody tests to sell their products as long as they registered with the FDA. The agency tightened those restrictions about six weeks later, but it has been criticized for standing in the way of other testing that could identify more people while they are contagious with COVID-19.
In May, the FDA issued an emergency use authorization for a drug called hydroxychloroquine, which was strongly promoted by President Donald Trump. There was little data supporting the approval, and the FDA reversed its decision in…